Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer.

Abstract

Epidermal growth factor receptor (EGFR) mutations are common driver genes in nonsmall-cell lung cancer and have different sensitivities to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). EGFR is divided into classic mutations and rare mutations. Classic mutations are well known, but the understanding of rare mutations is not sufficient. In this article, we summarize the clinical research and treatment progress of rare mutations for different EGFR-TKIs and provide a basis for clinical treatment decisions.

• Authors: Limeng Yu, Ruilin Wang, Yuhua Zhao, Yingxi Wu, Lili Wang, Haiyang Chen, Zhen He, Qiming Wang, Yufeng Wu
• Journal: Technology in cancer research & treatment (Technol Cancer Res Treat) 2023 Jan-Dec Vol. 22 Pg. 15330338231168466 ISSN: 1533-0338 [Electronic] United States
• PMID: 37078129 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)

Chemical References

• Protein Kinase Inhibitors
• ErbB Receptors

Topics

• Humans
• Lung Neoplasms (drug therapy, genetics)
• Protein Kinase Inhibitors (pharmacology, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics)
• ErbB Receptors (metabolism)
• Mutation